Alexey V. Danilov, MD, PhD

Alexey V. Danilov, MD, PhD, earned his medical degree and PhD at Yaroslavl State Medical Academy in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, Massachusetts. He is a physician-scientist with background in molecular biology and oncologic drug development and expertise in cancer cell signaling. He leads an independent research program in B-cell malignancies which bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics.

As a leader of the Lymphoma Center at the City of Hope National Medical Center, Dr. Danilov guides an effort in experimental therapeutics in lymphoid malignancies. In addition to pre-clinical focus on evaluation of novel targets in the ubiquitin-proteasome system and oncogenic role of cyclin-dependent kinase-9, his group performs correlative science on multiple clinical trials. He received peer-reviewed funding from the National Cancer Institute, Leukemia and Lymphoma Society, American Society of Hematology, Lymphoma Research Foundation and SWOG, and serves as Translational Medicine Chair at SWOG Lymphoma Committee.

Clinically, Dr. Danilov is a practicing medical oncologist specializing in the care of patients with CLL and lymphoma. Building on his pre-clinical discoveries, he launched multiple early-phase clinical trials with novel agents targeting Nedd8-activating enzyme, BTK, PI3K and SYK. As a member of industry and SWOG committees, he participates in drug development on a global scale.